ScreenerHero

NKTR Nektar Therapeutics

NAS · US · Healthcare · Biotechnology · nektar.com
40.26USD+0.88%Mkt Cap: 1.37B $P/E: —

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap1.37B USD
Enterprise Value814.24M USD
Revenue (TTM)54.59M USD
Gross Profit55.23M USD
Net Income (TTM)-164.08M USD
Revenue/Share2.25 USD
Last Price40.26 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees63
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.91
PEG0.31
EV/EBITDA-6.27
EV/Revenue14.92
P/S24.96
P/B1.51
EPS (TTM)-17.58
EPS (Forward)-10.20
52W Range
33.409% of range109.00
52W High109.00 USD
52W Low33.40 USD
Profitability
Gross Margin100.00%
Oper. Margin-412.23%
EBITDA Margin-238.05%
Profit Margin-297.07%
ROE-182.65%
ROA-58.51%
Growth
Revenue Growth-9.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-208.51M USD
CapEx (TTM)171.00K USD
FCF Margin-246.87%
FCF Yield-9.80%
Net Debt-548.41M USD
Net Debt/EBITDA4.22
Balance Sheet
Debt/Equity0.95
Current Ratio10.42
Quick Ratio9.71
Book Value/Sh26.46 USD
Cash/Share20.04 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:15
Split DateJun 9, 2025
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)141.40 USD
Upside (mean)+251.2%
Target Range50.00 USD – 192.00 USD
50.00+251.2% to mean192.00
# Analysts10
Ownership
Shares Out.34.14M
Float28.28M
Insiders0.38%
Institutions107.82%
Short Interest
Short Ratio8.8d
Short % Float18.52%
Short % Out.16.80%
Shares Short5.74M
Short (prev mo.)6.17M
Technical
SMA 5068.28 (-41.0%)
SMA 20065.35 (-38.4%)
Beta1.27
S&P 52W Chg16.45%
Avg Vol (30d)1.35M
Avg Vol (10d)2.49M
Technical Indicators
RSI (14)20.2
MACD-7.6410
MACD Signal-5.3008
MACD Hist.-2.3402
BB Upper81.86 USD
BB Middle59.36 USD
BB Lower36.86 USD
BB Width75.81%
ATR (14)3.973 USD
Vol Ratio (20d)0.84x